Inotiv, Inc. to Participate in the 2021 Colliers Institutional Investor ConferenceGlobeNewsWire • 08/31/21
Inotiv, Inc.'s (NOTV) CEO Robert Leasure on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/12/21
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel TherapiesGlobeNewsWire • 07/15/21
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma's BioReliance® portfolioGlobeNewsWire • 07/12/21
Inotiv, Inc. Broadens Pathology Services to Include Medical Device Pathology and Hires Nicolette Jackson to Lead EffortGlobeNewsWire • 06/28/21
Inotiv, Inc. (NOTV) CEO Robert Leasure on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/08/21
Inotiv, Inc. Announces Debt Financing and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.GlobeNewsWire • 04/30/21
Inotiv, Inc. to Report Second Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021GlobeNewsWire • 04/26/21
Inotiv, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter's Option to Purchase Additional SharesGlobeNewsWire • 04/23/21
Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for Second Quarter and Year to Date Fiscal 2021GlobeNewsWire • 04/20/21
Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc.GlobeNewsWire • 04/16/21
Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.GlobeNewsWire • 04/13/21
Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology OfferingGlobeNewsWire • 04/06/21